Physician profile
Mark S Burke
NPI 1730341074
$38,949.11
in general payments reported to CMS, 2019-2025
15 companies · $394 in 2025
The $394 reported for 2025 was less than what a typical Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $445).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $338 · 2020: $1,098 · 2021: $270 · 2022: $439 · 2023: $25K · 2024: $11K · 2025: $394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $24K · Travel and Lodging: $11K · Food and Beverage: $2,471.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $23,640.00 |
| Travel and Lodging | $10,693.07 |
| Food and Beverage | $2,470.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $35,655.16 | 2021-2025 | Integra, Omnigraft, Integra Dermal Regeneration Template |
| Acell, INC. | $927.71 | 2019-2020 | |
| Polynovo North America LLC | $557.10 | 2022-2025 | Novosorb Btm |
| Inspire Medical Systems, INC. | $392.55 | 2020 | |
| Tela Bio, INC. | $303.70 | 2019-2024 | Ovitex 2s |
| Abbvie INC. | $188.01 | 2025 | |
| Axogen | $180.07 | 2023-2024 | Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Ha+ Nerve Protector |
| Innovation Technologies INC | $153.50 | 2024 | Irrisept |
| Kerecis Limited | $146.83 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Abbott Laboratories | $146.31 | 2024 | Proclaim |
| Smith+Nephew, INC. | $135.98 | 2023 | Grafix Pl |
| Biocomposites INC | $109.08 | 2025 | Stimulan |
| Glaxosmithkline, LLC. | $22.16 | 2023 | Trelegy Ellipta |
| Medtronic, INC. | $17.55 | 2025 | Progrip |
| Baxter Healthcare | $13.40 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Burke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.